IXHL$0.3889
Chart
Performance
Key Stats
AI IXHL Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
HoldIncannex Healthcare Inc. shows promise in the emerging psychedelic therapy market but faces significant execution risk and early-stage financial challenges. Strong thematic potential is tempered by weak current fundamentals and volatile technicals.
Thematic
The company is at the forefront of developing novel treatments for debilitating conditions using psychedelics, tapping into a rapidly growing and significant market. Key thematic tailwinds include the destigmatization of mental health and advancements in neuroscience.
Fundamental
The company is in its early stages, characterized by minimal revenue, substantial operating losses, and negative earnings. While it has some cash reserves, ongoing funding needs are significant.
Technical
The stock has experienced extreme volatility, with a strong upward trend followed by a significant decline. Current indicators suggest a bearish short-term outlook with high volatility.
| Factor | Score |
|---|---|
| Psychedelic Therapy Market Growth | 90 |
| Clinical Trial Progress | 85 |
| Regulatory Landscape | 70 |
| Partnerships & Collaborations | 65 |
| Competitive Landscape | 70 |
| Factor | Score |
|---|---|
| Valuation | 10 |
| Profitability | 5 |
| Growth | 40 |
| Balance Sheet Health | 55 |
| Cash Flow | 15 |
| Debt Level | 85 |
| Factor | Score |
|---|---|
| Trend Analysis | 40 |
| Momentum | 50 |
| Volume Confirmation | 70 |
| Support & Resistance | 40 |
| Short-term Volatility | 20 |
AI Investing Checklist
Powered by LiveAIBullish Points (7)
Strong Market Position in Biopharmaceutical Sector
Incannex Healthcare Inc. is a clinical-stage biopharmaceutical company focused on developing psychedelic medicines and therapies for chronic diseases, operating in a high-growth and innovative sector.
Diverse and Promising Pipeline
The company has multiple drug candidates in clinical development for significant conditions such as obstructive sleep apnea (IHL-42X), generalized anxiety disorder (PSX-001), and rheumatoid arthritis/inflammatory diseases (IHL-675A), indicating a robust R&D strategy.
Bearish Points (9)
Significant Price Decline
The current price of $1.05 represents a substantial drop of -35.58% from its previous close. The 52-week range of $0.08-$3.12 indicates high historical volatility.
Negative Long-Term Performance
The stock has experienced significant negative performance over longer periods, with a 6-month return of -37.5%, Year-to-Date (YTD) return of -47.89%, and a 1-year return of -50.24%, indicating sustained downward pressure.
Calendar
May 2025
15
Next Earnings Date
H: $
A: $
L: $
H: 312.00K
A: 312.00K
L: 312.00K
Profile
Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research, development, manufacture, sale, and distribution of psychedelic medicines and therapies for patients with chronic diseases in Australia. The company develops IHL-42X, an oral fixed dose combination of dronabinol and acetazolamide that has completed Phase 2/3 clinical trial for the treatment of obstructive sleep apnea; and PSX-001, an oral synthetic psilocybin treatment in Phase 2b clinical development for patients with generalized anxiety disorder. It is also developing IHL-675A, an oral fixed dose combination drug containing synthetic cannabidiol and hydroxychloroquine sulphate in Phase 2 clinical trial to treat rheumatoid arthritis, as well as lung inflammation, acute respiratory disease, chronic obstructive pulmonary disease, asthma, bronchitis, inflammatory bowel disease, colitis, and Crohn's disease. Incannex Healthcare Inc. is headquartered in Sydney, Australia.
Seasonals
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Cash Flow
Related Companies
Powered by LiveAIWeight: 95
A leading clinical-stage mental health care company focused on psilocybin therapy for treatment-resistant depression, a direct competitor in psychedelic medicine development.
Weight: 93
A clinical-stage biopharmaceutical company focused on developing 5-MeO-DMT for the treatment of depression, directly aligned with psychedelic therapy research.
Weight: 92
A clinical-stage biopharmaceutical company developing psychedelic-based therapies for mental health conditions, a direct peer in the psychedelic drug development space.
Weight: 90
A clinical-stage psychedelic medicine company targeting mental health and addiction disorders with novel compounds, directly competing in a similar therapeutic area.